See more : Southern Infosys Limited (SOUTHERNIN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Enzo Biochem, Inc. (ENZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enzo Biochem, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- 55 North Mining Inc. (FFF.CN) Income Statement Analysis – Financial Results
- Evercel, Inc. (EVRC) Income Statement Analysis – Financial Results
- Glance Finance Limited (GLANCE.BO) Income Statement Analysis – Financial Results
- Black Iron Inc. (BKIRF) Income Statement Analysis – Financial Results
- LandBridge Company LLC (LB) Income Statement Analysis – Financial Results
Enzo Biochem, Inc. (ENZ)
About Enzo Biochem, Inc.
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.91M | 31.06M | 107.07M | 117.73M | 76.02M | 81.17M | 104.71M | 107.80M | 102.77M | 97.60M | 95.95M | 93.71M | 103.08M | 102.03M | 97.08M | 89.57M | 77.80M | 52.91M | 39.83M | 43.40M | 41.64M | 52.77M | 54.02M | 58.41M | 50.03M | 44.30M | 40.40M | 34.90M | 34.50M | 31.70M | 22.80M | 20.00M | 20.50M | 19.80M | 19.40M | 12.10M | 9.10M | 8.70M | 7.30M |
| Cost of Revenue | 17.28M | 19.50M | 65.10M | 64.15M | 52.25M | 57.92M | 60.39M | 59.48M | 57.19M | 54.77M | 54.27M | 54.84M | 55.97M | 53.82M | 52.12M | 53.06M | 40.22M | 23.23M | 16.09M | 14.74M | 13.10M | 11.78M | 10.85M | 17.42M | 14.10M | 14.30M | 13.80M | 13.80M | 13.60M | 12.10M | 9.30M | 6.70M | 6.20M | 21.20M | 5.20M | 3.60M | 1.90M | 1.70M | 1.40M |
| Gross Profit | 14.63M | 11.57M | 41.97M | 53.58M | 23.77M | 23.25M | 44.33M | 48.33M | 45.58M | 42.83M | 41.68M | 38.87M | 47.11M | 48.21M | 44.97M | 36.51M | 37.57M | 29.68M | 23.74M | 28.66M | 28.54M | 40.99M | 43.17M | 40.98M | 35.93M | 30.00M | 26.60M | 21.10M | 20.90M | 19.60M | 13.50M | 13.30M | 14.30M | -1.40M | 14.20M | 8.50M | 7.20M | 7.00M | 5.90M |
| Gross Profit Ratio | 45.86% | 37.24% | 39.20% | 45.51% | 31.27% | 28.64% | 42.33% | 44.83% | 44.35% | 43.88% | 43.44% | 41.48% | 45.70% | 47.25% | 46.32% | 40.76% | 48.30% | 56.09% | 59.60% | 66.03% | 68.53% | 77.67% | 79.92% | 70.17% | 71.81% | 67.72% | 65.84% | 60.46% | 60.58% | 61.83% | 59.21% | 66.50% | 69.76% | -7.07% | 73.20% | 70.25% | 79.12% | 80.46% | 80.82% |
| Research & Development | 2.64M | 3.90M | 3.77M | 3.25M | 4.45M | 3.18M | 3.21M | 2.93M | 3.52M | 3.35M | 3.14M | 3.89M | 6.29M | 7.81M | 9.70M | 9.22M | 8.64M | 9.39M | 7.90M | 8.45M | 8.08M | 8.31M | 6.18M | 6.08M | 5.43M | 4.40M | 4.00M | 3.60M | 3.10M | 2.40M | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.36M | 27.20M | 53.71M | 44.91M | 49.69M | 44.27M | 44.47M | 44.01M | 43.59M | 41.07M | 41.80M | 43.65M | 51.65M | 48.90M | 52.09M | 45.51M | 43.72M | 41.25M | 35.99M | 30.51M | 32.69M | 28.30M | 28.00M | 25.67M | 23.49M | 20.40M | 19.90M | 16.00M | 17.50M | 17.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -2.63M | 345.00K | 577.00K | 400.00K | 437.00K | 374.00K | 580.00K | 649.00K | 601.00K | 556.00K | 440.00K | 302.00K | 237.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.72M | 27.20M | 53.71M | 44.91M | 42.96M | 44.27M | 44.47M | 44.01M | 43.59M | 41.07M | 41.80M | 43.65M | 51.65M | 48.90M | 52.09M | 45.51M | 43.72M | 41.25M | 35.99M | 30.51M | 32.69M | 28.30M | 28.00M | 25.67M | 23.49M | 20.40M | 19.90M | 16.00M | 17.50M | 17.10M | 10.60M | 16.90M | 12.90M | 0.00 | 15.80M | 12.20M | 9.60M | 9.60M | 4.50M |
| Other Expenses | 0.00 | 380.00K | -1.19M | 6.91M | 488.00K | 382.00K | 168.00K | 125.00K | 122.00K | 95.00K | 194.00K | 5.00K | 5.10M | 4.43M | 3.48M | 5.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.93M | 1.90M | 1.90M | 1.80M | 1.80M | 1.80M | 1.50M | 1.50M | 700.00K | 1.20M | 500.00K | 300.00K | 0.00 | 500.00K | 300.00K |
| Operating Expenses | 27.00M | 31.11M | 57.47M | 48.16M | 47.41M | 47.44M | 51.37M | 49.71M | 49.45M | 46.70M | 48.01M | 52.04M | 63.05M | 61.14M | 65.28M | 60.57M | 52.36M | 50.64M | 43.89M | 38.96M | 40.77M | 36.61M | 34.18M | 31.75M | 30.84M | 26.70M | 25.80M | 21.40M | 22.40M | 21.30M | 13.90M | 18.40M | 13.60M | 1.20M | 16.30M | 12.50M | 10.10M | 10.10M | 4.80M |
| Cost & Expenses | 44.27M | 50.60M | 122.58M | 112.31M | 99.66M | 105.36M | 111.75M | 109.19M | 106.64M | 101.48M | 102.27M | 106.87M | 119.02M | 114.96M | 117.39M | 113.63M | 92.58M | 73.87M | 59.98M | 53.71M | 53.88M | 48.40M | 45.03M | 49.18M | 44.94M | 41.00M | 39.60M | 35.20M | 36.00M | 33.40M | 23.20M | 25.10M | 19.80M | 22.40M | 21.50M | 16.10M | 12.00M | 11.80M | 6.20M |
| Interest Income | 3.54M | 0.00 | 178.00K | 8.00K | 454.00K | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 581.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 197.00K | 0.00 | 159.00K | 0.00 | 0.00 | 0.00 | 9.78M | 2.58M | 0.00 | 0.00 | 7.14M | 11.52M | 49.99M | 0.00 | 3.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.00M | 0.00 | 0.00 | 2.70M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.27M | 2.68M | 2.83M | 2.65M | 2.78M | 3.04M | 3.13M | 3.60M | 3.84M | 3.79M | 3.97M | 4.61M | 4.48M | 4.47M | 4.27M | 3.46M | 2.15M | 1.19M | 1.12M | 2.33M | 2.36M | 1.81M | 2.15M | 2.25M | 1.93M | 1.90M | 1.90M | 1.80M | 1.80M | 1.80M | 1.50M | 1.50M | 700.00K | 1.20M | 500.00K | 300.00K | 500.00K | 500.00K | 300.00K |
| EBITDA | -8.35M | -20.94M | -15.01M | 3.35M | -27.59M | -24.16M | -3.91M | 1.09M | -6.56M | -1.21M | -5.73M | -14.29M | -11.46M | -8.35M | -17.99M | -20.02M | -8.75M | -19.78M | -19.03M | -7.97M | -9.87M | 6.18M | 11.14M | 11.48M | 7.01M | 5.20M | 2.70M | 1.50M | 300.00K | 100.00K | 1.10M | -3.60M | 1.40M | -1.40M | -1.60M | -3.70M | -2.40M | -2.60M | 1.40M |
| EBITDA Ratio | -26.16% | -39.01% | -10.23% | 10.64% | -19.78% | 100.00% | 100.00% | 100.00% | 100.00% | -1.87% | 1.26% | -3.02% | 13.14% | -8.38% | -14.50% | -22.99% | -16.50% | -42.48% | -47.78% | -50.63% | -23.70% | 11.71% | 20.63% | 19.66% | 14.01% | 11.74% | 1.98% | -0.86% | 18.26% | -35.65% | -6.14% | -13.00% | 8.78% | 16.67% | -19.59% | -61.16% | -59.34% | -67.82% | -9.59% |
| Operating Income | -9.82M | -24.74M | -15.51M | 9.88M | -23.64M | 78.13M | -12.16M | -3.07M | 47.00M | -1.21M | -10.18M | -18.98M | -40.48M | -12.93M | -22.06M | -24.06M | -14.79M | -20.97M | -20.15M | -10.31M | -12.23M | 4.37M | 8.99M | 9.23M | 5.08M | 3.30M | 800.00K | -300.00K | -1.50M | -1.70M | -400.00K | -5.10M | 700.00K | -2.60M | -2.10M | -4.00M | -2.90M | -3.10M | 1.10M |
| Operating Income Ratio | -30.77% | -79.64% | -14.48% | 8.39% | -31.09% | 96.26% | -11.62% | -2.84% | 45.73% | -1.24% | -10.61% | -20.25% | -39.27% | -12.67% | -22.72% | -26.86% | -19.01% | -39.63% | -50.60% | -23.74% | -29.37% | 8.28% | 16.64% | 15.80% | 10.16% | 7.45% | 1.98% | -0.86% | -4.35% | -5.36% | -1.75% | -25.50% | 3.41% | -13.13% | -10.82% | -33.06% | -31.87% | -35.63% | 15.07% |
| Total Other Income/Expenses | 0.00 | -286.00K | -3.31M | 7.18M | 1.85M | 29.68M | 746.00K | 644.00K | 56.92M | -1.09M | 275.00K | 31.00K | -442.00K | 105.00K | -203.00K | -70.00K | 3.89M | 7.79M | 3.14M | 15.52M | 1.15M | 1.36M | 1.35M | 3.00M | 2.58M | 2.10M | 1.80M | 1.90M | -6.00M | 11.40M | 2.60M | -1.20M | -1.80M | 2.60M | -1.80M | 0.00 | 3.00M | -500.00K | 1.00M |
| Income Before Tax | -9.82M | -25.02M | -18.26M | 7.88M | -28.52M | 2.49M | -11.42M | -2.42M | 46.52M | -2.29M | -9.91M | -18.95M | -40.92M | -12.82M | -22.26M | -23.48M | -10.89M | -13.18M | -17.01M | 5.22M | -11.08M | 5.73M | 10.34M | 12.23M | 7.67M | 5.40M | 2.60M | 1.60M | -7.50M | 9.70M | 2.20M | -6.30M | -1.10M | -2.60M | -3.90M | -4.00M | 100.00K | -3.60M | 2.10M |
| Income Before Tax Ratio | -30.77% | -80.56% | -17.06% | 6.69% | -37.52% | 3.07% | -10.90% | -2.25% | 45.26% | -2.35% | -10.32% | -20.22% | -39.70% | -12.57% | -22.93% | -26.21% | -14.00% | -24.90% | -42.71% | 12.02% | -26.61% | 10.85% | 19.14% | 20.94% | 15.33% | 12.19% | 6.44% | 4.58% | -21.74% | 30.60% | 9.65% | -31.50% | -5.37% | -13.13% | -20.10% | -33.06% | 1.10% | -41.38% | 28.77% |
| Income Tax Expense | 0.00 | 12.30M | 4.32M | 4.45M | 5.37M | 101.27M | -1.10M | 82.00K | 1.23M | -7.00K | 72.00K | -712.00K | -1.65M | 137.00K | -28.00K | -87.00K | -239.00K | 85.00K | -1.34M | 2.21M | -4.85M | 1.88M | 3.42M | 5.42M | 1.04M | -1.10M | -800.00K | 100.00K | 200.00K | 4.10M | -2.90M | 100.00K | 100.00K | 12.90M | 200.00K | 100.00K | 600.00K | -2.00M | 600.00K |
| Net Income | -26.08M | 20.29M | -22.58M | 3.43M | -33.89M | -98.78M | -10.32M | -2.50M | 45.29M | -2.29M | -9.98M | -18.24M | -39.27M | -12.96M | -22.23M | -23.56M | -10.65M | -13.26M | -15.67M | 3.00M | -6.23M | 3.84M | 6.92M | 6.81M | 6.62M | 6.50M | 3.40M | 1.50M | -7.70M | 5.60M | 5.30M | -6.90M | -600.00K | -10.80M | -4.10M | -4.10M | -3.50M | -1.60M | 1.50M |
| Net Income Ratio | -81.73% | 65.32% | -21.09% | 2.91% | -44.58% | -121.70% | -9.86% | -2.32% | 44.06% | -2.34% | -10.40% | -19.46% | -38.09% | -12.70% | -22.90% | -26.31% | -13.69% | -25.06% | -39.34% | 6.92% | -14.96% | 7.28% | 12.82% | 11.66% | 13.24% | 14.67% | 8.42% | 4.30% | -22.32% | 17.67% | 23.25% | -34.50% | -2.93% | -54.55% | -21.13% | -33.88% | -38.46% | -18.39% | 20.55% |
| EPS | -0.51 | -1.27 | -0.46 | 0.07 | -0.71 | -2.09 | -0.22 | -0.05 | 0.98 | -0.05 | -0.23 | -0.46 | -1.01 | -0.34 | -0.59 | -0.63 | -0.29 | -0.38 | -0.49 | 0.09 | -0.20 | 0.11 | 0.22 | 0.22 | 0.22 | 0.21 | 0.12 | 0.05 | -0.27 | 0.19 | 0.19 | -0.29 | -0.03 | -0.71 | -0.26 | -0.27 | -0.24 | -0.11 | 0.09 |
| EPS Diluted | -0.51 | -1.27 | -0.46 | 0.07 | -0.71 | -2.08 | -0.22 | -0.05 | 0.97 | -0.05 | -0.23 | -0.46 | -1.01 | -0.34 | -0.59 | -0.63 | -0.29 | -0.38 | -0.49 | 0.09 | -0.20 | 0.11 | 0.22 | 0.21 | 0.20 | 0.21 | 0.11 | 0.05 | -0.27 | 0.19 | 0.18 | -0.29 | -0.03 | -0.71 | -0.26 | -0.27 | -0.24 | -0.11 | 0.09 |
| Weighted Avg Shares Out | 50.90M | 49.16M | 48.59M | 48.19M | 47.70M | 47.35M | 46.91M | 46.35M | 46.15M | 45.36M | 42.56M | 39.61M | 38.80M | 38.36M | 38.00M | 37.51M | 36.88M | 35.02M | 32.22M | 32.10M | 31.70M | 32.97M | 31.36M | 31.25M | 30.79M | 30.31M | 29.97M | 29.47M | 28.84M | 29.38M | 28.05M | 24.00M | 18.26M | 15.29M | 15.60M | 15.13M | 14.69M | 14.98M | 16.60M |
| Weighted Avg Shares Out (Dil) | 50.90M | 49.16M | 48.59M | 48.33M | 47.70M | 47.48M | 46.97M | 46.35M | 46.60M | 45.36M | 42.56M | 39.61M | 38.80M | 38.36M | 38.00M | 37.51M | 36.88M | 35.02M | 32.22M | 32.76M | 31.70M | 33.78M | 32.33M | 32.56M | 32.80M | 30.97M | 31.29M | 29.47M | 28.91M | 29.38M | 29.33M | 24.00M | 18.26M | 15.29M | 15.60M | 15.13M | 14.69M | 14.98M | 16.60M |
Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin
NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,899,827 entitled “Antibodies Specific for Sulfation Sites of...
ENZO BIOCHEM'S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTEES
NEW YORK, NY, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Enzo Board of Directors has formed two new committees to support strategy related...
Roumell Announces Preliminary Annual Meeting Results for Enzo Biochem, Inc.
CHEVY CHASE, Md., Jan. 5, 2021 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock (the "Common Stock") of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or "the Company"), today announced the preliminary...
ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR TESTING POOLED SAMPLES ON THREE PLATFORMS INCLUDING COMPANY'S GENFLEX™ PROPRIETARY SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2
- Use of pooled sampling with Enzo's molecular diagnostic technology can help rapidly expand the number of people tested for COVID-19 -
Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend That Shareholders Vote AGAINST Elazar Rabbani at Enzo's Upcoming Annual Meeting
CHEVY CHASE, Md., Dec. 31, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or "the Company"), today acknowledged that each of Institutional Shareholder...
ENZO RESPONDS AFTER REVIEWING THE POSITION OF INSTITUTIONAL SHAREHOLDER SERVICES
NEW YORK, NY, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the position of Institutional Shareholder Services (“ISS”) regarding the Company's executive...
Roumell Asset Management Files Definitive Proxy Statement and Sends Letter to Enzo Biochem Shareholders
CHEVY CHASE, Md., Dec. 24, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc.(NYSE: ENZ) ("Enzo" or "the Company"), filed definitive proxy materials yesterday with the Securities...
Enzo Biochem: Betting On The Activists Now
Enzo Biochem, Inc. has continued to underperform its peers and the general markets despite the tailwind from the pandemic outbreak. In November 2020, two investment funds went activist on the company, demanding the resignation of the CEO, adding new board...
Enzo Biochem, Inc. (ENZ) Q1 2021 Results - Earnings Call Transcript
Enzo Biochem, Inc. (ENZ) Q1 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports